Literature DB >> 35378029

Is There Any Role for Device Therapies in Resistant Hypertension? Commentary.

Tara I Chang1.   

Abstract

Entities:  

Keywords:  Hypertension; Resistant hypertension; blood pressure

Mesh：

Year:  2020        PMID： 35378029      PMCID： PMC8808495          DOI： 10.34067/KID.0000682019

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  13 in total

1.  Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.

Authors:  Uta C Hoppe; Mathias-Christoph Brandt; Rolf Wachter; Joachim Beige; Lars Christian Rump; Abraham A Kroon; Adam W Cates; Eric G Lovett; Hermann Haller
Journal:  J Am Soc Hypertens       Date:  2012-06-12

2.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

3.  Use of Directly Observed Therapy to Assess Treatment Adherence in Patients With Apparent Treatment-Resistant Hypertension.

Authors:  Marcel Ruzicka; Frans H H Leenen; Tim Ramsay; Ann Bugeja; Cedric Edwards; Brendan McCormick; Swapnil Hiremath
Journal:  JAMA Intern Med       Date:  2019-10-01       Impact factor: 21.873

4.  Prevalence of Apparent Treatment-Resistant Hypertension in the United States.

Authors:  Robert M Carey; Swati Sakhuja; David A Calhoun; Paul K Whelton; Paul Muntner
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

5.  Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial.

Authors:  Rosa L de Jager; Erik M van Maarseveen; Michiel L Bots; Peter J Blankestijn
Journal:  Br J Clin Pharmacol       Date:  2017-10-10       Impact factor: 4.335

6.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.

Authors:  Michel Azizi; Roland E Schmieder; Felix Mahfoud; Michael A Weber; Joost Daemen; Justin Davies; Jan Basile; Ajay J Kirtane; Yale Wang; Melvin D Lobo; Manish Saxena; Lida Feyz; Florian Rader; Philipp Lurz; Jeremy Sayer; Marc Sapoval; Terry Levy; Kintur Sanghvi; Josephine Abraham; Andrew S P Sharp; Naomi D L Fisher; Michael J Bloch; Helen Reeve-Stoffer; Leslie Coleman; Christopher Mullin; Laura Mauri
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

7.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.

Authors:  David E Kandzari; Michael Böhm; Felix Mahfoud; Raymond R Townsend; Michael A Weber; Stuart Pocock; Konstantinos Tsioufis; Dimitrios Tousoulis; James W Choi; Cara East; Sandeep Brar; Sidney A Cohen; Martin Fahy; Garrett Pilcher; Kazuomi Kario
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

8.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

9.  Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry.

Authors:  Felix Mahfoud; Michael Böhm; Roland Schmieder; Krzysztof Narkiewicz; Sebastian Ewen; Luis Ruilope; Markus Schlaich; Bryan Williams; Martin Fahy; Giuseppe Mancia
Journal:  Eur Heart J       Date:  2019-11-01       Impact factor: 29.983

10.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Authors:  Raymond R Townsend; Felix Mahfoud; David E Kandzari; Kazuomi Kario; Stuart Pocock; Michael A Weber; Sebastian Ewen; Konstantinos Tsioufis; Dimitrios Tousoulis; Andrew S P Sharp; Anthony F Watkinson; Roland E Schmieder; Axel Schmid; James W Choi; Cara East; Anthony Walton; Ingrid Hopper; Debbie L Cohen; Robert Wilensky; David P Lee; Adrian Ma; Chandan M Devireddy; Janice P Lea; Philipp C Lurz; Karl Fengler; Justin Davies; Neil Chapman; Sidney A Cohen; Vanessa DeBruin; Martin Fahy; Denise E Jones; Martin Rothman; Michael Böhm
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.